ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Caspofungin: Pediatric drug information

Caspofungin: Pediatric drug information
(For additional information see "Caspofungin: Drug information" and see "Caspofungin: Patient drug information")

For abbreviations, symbols, and age group definitions used in Lexicomp (show table)
Brand Names: US
  • Cancidas
Brand Names: Canada
  • Cancidas
Therapeutic Category
  • Antifungal Agent, Echinocandin;
  • Antifungal Agent, Systemic
Dosing: Neonatal

Dosage guidance:

Clinical considerations: Caspofungin treatment duration should be based on patient status and clinical response.

Candidiasis, invasive infections

Candidiasis, invasive infections: Limited data available: IV:

BSA-directed dosing: 25 mg/m2/dose once daily (Ref); dosing based on a pharmacokinetic study of 18 neonates (PNA: <12 weeks; GA ≥28 weeks (all except one patient); weight at enrollment: ≥500 g; most [n=16] were ≥1 kg); results showed similar serum concentrations to standard adult doses. Reported trough concentrations were slightly elevated and not correlated with increased adverse events (Ref).

Weight-directed dosing: 2 mg/kg/dose once daily; treatment should continue for at least 2 weeks after the first negative blood culture and signs and symptoms have resolved (Ref); dosing based on a prospective, randomized, double-blind study and a case series; the prospective trial enrolled 32 patients with invasive candidiasis and randomized them to receive caspofungin (n=15; GA: 27.9 ± 1.3 weeks; PNA at onset of candida infection: 21.1 ± 3.1 days) or amphotericin B as initial treatment; results showed that the caspofungin group had a significantly higher response rate compared to the amphotericin B group (86.7% favorable response vs 41.7%); the caspofungin group also experienced significantly fewer adverse effects (Ref); the case series included seven premature neonates (GA: 23 to 24 weeks, PNA at treatment, range: 13 to 53 days) with Candida infections refractory to amphotericin B; results showed this regimen to be effective and well tolerated for the treatment of Candida parapsilosis and Candida albicans (Ref).

Dosing: Pediatric

Dosage guidance:

Clinical considerations: Caspofungin treatment duration should be based on patient status and clinical response.

Aspergillosis, invasive; treatment

Aspergillosis, invasive; treatment: Note: Guidelines recommend caspofungin for salvage therapy or where other antifungals are contraindicated; not recommended for routine use for primary treatment (Ref). Infants ≥3 months, Children, and Adolescents <18 years: IV: Initial 70 mg/m2/dose on day 1, then 50 mg/m2/dose once daily; may increase to 70 mg/m2/dose once daily if clinical response inadequate; maximum dose: 70 mg/dose.

Fungal infections, empiric therapy in neutropenic patients

Fungal infections, empiric therapy in neutropenic patients: Infants ≥3 months, Children, and Adolescents <18 years: IV: Initial dose: 70 mg/m2/dose on day 1, then 50 mg/m2/dose once daily; may increase to 70 mg/m2/dose once daily if clinical response inadequate; maximum dose: 70 mg/dose.

Fungal infections, prophylaxis in patients with acute myeloid leukemia

Fungal infections, prophylaxis in patients with acute myeloid leukemia: Limited data available: Infants ≥3 months, Children, and Adolescents: IV: Initial 70 mg/m2/dose on day 1 (maximum dose: 70 mg/dose), then 50 mg/m2/dose once daily (maximum dose: 50 mg/dose); begin therapy 24 to 72 hours following completion of each chemotherapy cycle and continue until ANC 100 to 500/µL following nadir or until next chemotherapy cycle, whichever occurs first (Ref).

Fungal infections, prophylaxis in allogeneic hematopoietic stem cell transplantation recipients

Fungal infections, prophylaxis in allogeneic hematopoietic stem cell transplantation recipients: Limited data available: Infants ≥8 months, Children, and Adolescents: IV: 50 mg/m2/dose once daily; maximum dose: 50 mg/dose (Ref); some studies used a loading dose (Ref); guidelines recommend administering antifungal prophylaxis from the start of conditioning through engraftment (Ref).

Candida infections, treatment; independent of HIV status

Candida infections, treatment; independent of HIV status:

Infants <3 months: Limited data available: IV: 25 mg/m2/dose once daily; dosing based on a pharmacokinetic study of 18 infants (PNA ≤12 weeks) that showed similar serum concentrations to standard adult doses (50 mg/day). Reported trough concentrations were slightly elevated and not correlated with increased adverse events (Ref).

Infants ≥3 months, Children, and Adolescents <18 years: IV: Initial 70 mg/m2/dose on day 1, then 50 mg/m2/dose once daily; may increase to 70 mg/m2/dose once daily if clinical response inadequate; maximum dose: 70 mg/dose. For esophageal disease, treat 14 to 21 days (Ref). For candidemia, treat until 2 weeks after the last positive blood culture.

Adolescents ≥18 years: IV: Initial 70 mg on day 1, then 50 mg once daily (Ref); for candidemia, treat until 2 weeks after the last positive blood culture and symptom resolution, and longer if neutropenia warrants; for esophageal disease, treat for 14 to 21 days. For esophageal disease, a higher rate of relapse has been reported with echinocandins than with fluconazole (Ref). Transition to fluconazole is recommended in clinically stable patients with fluconazole-susceptible isolates and negative repeat cultures (Ref).

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Pediatric

Infants ≥3 months, Children, and Adolescents: No adjustment needed

End-stage renal disease (ESRD) requiring dialysis: Poorly dialyzed; no supplemental dose or dosage adjustment necessary in patients on intermittent hemodialysis (IHD). No supplemental dose or dosage adjustment needed in peritoneal dialysis or continuous renal replacement therapy (eg, CVVHD) (Ref).

Dosing: Hepatic Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer's labeling (has not been studied); based on experience in adult patients, dosage reduction may be necessary; use with caution.

Dosing: Adult

(For additional information see "Caspofungin: Drug information")

Aspergillosis, invasive

Aspergillosis, invasive (including disseminated and extrapulmonary) (alternative agent):

Note: Reserve for salvage therapy, typically as part of an appropriate combination regimen. Monotherapy is further reserved for patients who are intolerant of or refractory to azoles and polyenes (Ref); for patients with severe or progressive infection, some experts use as initial therapy in combination with voriconazole (Ref).

IV: 70 mg on day 1, then 50 mg once daily (Ref); if inadequate response, may increase dose to 70 mg once daily (Ref).

Duration: When given as monotherapy, the minimum duration is 6 to 12 weeks depending on degree/duration of immunosuppression, disease site, and response to therapy (Ref); immunosuppressed patients may require more prolonged treatment (Ref). When given as part of a combination regimen, the optimal duration is uncertain. Some experts have given an echinocandin for ~2 weeks in combination with voriconazole before step-down to voriconazole monotherapy (Ref).

Candidiasis

Candidiasis:

Candidemia (neutropenic and nonneutropenic patients), including disseminated candidiasis: IV: 70 mg on day 1, then 50 mg once daily. Total duration (including oral step-down therapy) is ≥14 days after first negative blood culture and continues until signs/symptoms of candidemia and neutropenia, if present, have resolved; metastatic complications warrant a longer duration (Ref).

Cardiac device infection (including implantable cardiac defibrillator, pacemaker, ventricular assist device) (off-label use) : IV: 150 mg once daily; step down to azole therapy in clinically stable patients with susceptible isolates and negative repeat cultures; total antifungal duration is ≥4 weeks after device removal for isolated generator pocket infection and ≥6 weeks after device removal for wire infection (Ref).

Chronic disseminated (hepatosplenic) (off-label use): IV: 70 mg on day 1, then 50 mg once daily for several weeks, followed by oral azole step-down therapy until lesion resolution and through periods of immunosuppression (Ref).

Empiric therapy, suspected invasive candidiasis (nonneutropenic ICU patients) (off-label use):

Note: Antifungal therapy is not routinely warranted for initial management of nonneutropenic patients with sepsis. Consider use for critically ill patients with unexplained fever or unexplained hypotension despite broad-spectrum antimicrobial therapy and risk factors for invasive candidiasis (eg, indwelling venous catheter, hemodialysis, trauma or burns, recent surgery, parenteral nutrition) (Ref).

IV: 70 mg on day 1, then 50 mg once daily. For those who improve, continue empiric antifungal therapy for 2 weeks; consider discontinuing after 4 to 5 days in patients with no evidence of invasive candidiasis and no clinical response (Ref).

Endocarditis, native or prosthetic valve (off-label use): IV: 150 mg once daily(Ref); step down to azole therapy in clinically stable patients with susceptible isolates and negative repeat cultures; total antifungal duration is ≥6 weeks after valve replacement surgery, with longer duration for perivalvular abscesses, other complications, or a nonsurgical approach (Ref).

Esophageal, refractory disease (alternative agent):

Note: Reserve for fluconazole-refractory disease in patients who require IV therapy (eg, severe disease) (Ref).

IV: 70 mg on day 1, then 50 mg once daily (Ref); some experts give 50 mg once daily without a loading dose (Ref), and other experts prefer 70 mg once daily (Ref). Transition to an oral antifungal once patient tolerates oral intake if susceptibility allows; total antifungal duration is 14 to 28 days (Ref).

Intra-abdominal infection (eg, peritonitis, abdominal abscess): IV: 70 mg on day 1, then 50 mg once daily. Total duration (including oral step-down therapy) is ≥14 days and continues until source control and clinical resolution (Ref).

Oropharyngeal, refractory disease (alternative therapy) (off-label use):

Note: Reserve for fluconazole-refractory disease in patients who require IV therapy (eg, severe disease) (Ref).

IV: 70 mg on day 1, then 50 mg once daily. Transition to an oral antifungal once patient tolerates oral intake if susceptibility allows; total antifungal duration is 14 to 28 days (Ref).

Osteoarticular infection (osteomyelitis or septic arthritis) (off-label use): IV: 70 mg on day 1, then 50 to 70 mg once daily for ≥2 weeks; total duration of therapy (including oral step-down therapy) is 6 to 12 months for osteomyelitis and ≥6 weeks for septic arthritis (Ref).

Thrombophlebitis, suppurative (off-label use): IV: 150 mg once daily; continue antifungal therapy until catheter removed and thrombus resolved, and for ≥2 weeks after candidemia (if present) has cleared (Ref).

Neutropenic fever, empiric antifungal therapy

Neutropenic fever, empiric antifungal therapy (alternative agent):

Note: Recommended for patients with persistent or recurrent fever after ≥4 days of antimicrobial therapy when the duration of neutropenia is expected to exceed 7 days (Ref). Some experts reserve for patients without suspicion of mold infection (eg, pulmonary nodules) (Ref).

IV: 70 mg on day 1, then 50 mg once daily (Ref).

Prophylaxis against invasive fungal infections

Prophylaxis against invasive fungal infections (off-label use):

Hematologic malignancy or hematopoietic cell transplant (alternative agent):

Note: Some experts reserve for patients at low risk for mold infection (Ref).

IV: 50 mg once daily. Duration is at least until resolution of neutropenia and varies based on degree and duration of immunosuppression (Ref).

Solid organ transplant (alternative agent): IV: 50 mg once daily; duration varies based on patient risk factors and transplant center protocol (Ref).

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Adult

The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.

Altered kidney function: No dosage adjustment necessary for any degree of kidney dysfunction (Ref).

Hemodialysis, intermittent (thrice weekly): Poorly dialyzed: No supplemental dose or dosage adjustment necessary (Ref).

Peritoneal dialysis: Unlikely to be significantly dialyzed (highly protein bound): No dosage adjustment necessary (Ref).

CRRT: Poorly dialyzed (Ref): No dosage adjustment necessary (Ref). Note: Significant variability in caspofungin pharmacokinetics has been observed in critically ill patients (Ref) and those on renal replacement therapies (Ref). Results of a Monte Carlo simulation suggest that instead of standard dosing (ie, 70 mg × 1 followed by 50 mg daily), a larger loading dose (ie, 100 mg) and maintenance dose of 50 mg once daily in patients <80 kg or 70 mg once daily in patients >80 kg increases the probability of achieving pharmacodynamic targets (Ref).

PIRRT (eg, sustained, low-efficiency diafiltration): Unlikely to be significantly dialyzed: No dosage adjustment necessary (Ref). Note: Significant variability in caspofungin pharmacokinetics has been observed in critically ill patients (Ref) and those on renal replacement therapies (Ref). Results of a Monte Carlo simulation suggest that instead of standard dosing (ie, 70 mg × 1 followed by 50 mg daily), a larger loading dose (ie, 100 mg) and maintenance dose of 50 mg once daily in patients <80 kg or 70 mg once daily in patients >80 kg increases the probability of achieving pharmacodynamic targets in patients on CRRT (Ref); these results are likely to be applicable to critically ill patients receiving PIRRT therapies as well (Ref).

Dosing: Hepatic Impairment: Adult

Mild impairment (Child-Pugh class A): No dosage adjustment necessary.

Moderate impairment (Child-Pugh class B): 70 mg on day 1 (where recommended), followed by 35 mg once daily(Ref); however, pharmacokinetic data suggest that this dose reduction may result in suboptimal drug exposure (Ref).

Severe impairment (Child-Pugh class C): There are no dosage adjustments provided in the manufacturer's labeling. Subsequent pharmacokinetic data suggest that degree of impairment (Child-Pugh class B or C) does not further decrease clearance of caspofungin and patients with severe impairment can be dosed the same as patients with moderate impairment (Ref).

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.

>10%:

Cardiovascular: Hypotension (adults: 3% to 20%; infants, children, and adolescents: 9%), peripheral edema (adults: 6% to 11%), tachycardia (7% to 11%)

Central nervous system: Chills (adults: 9% to 23%; infants, children, and adolescents: 13%), headache (9% to 15%)

Dermatologic: Skin rash (4% to 23%)

Gastrointestinal: Diarrhea (adults: 6% to 27%; infants, children, and adolescents: 7%), vomiting (6% to 17%), nausea (adults: 5% to 15%; infants, children, and adolescents: 4%)

Hematologic & oncologic: Decreased hemoglobin (adults: 18% to 21%), decreased hematocrit (adults: 13% to 18%), decreased white blood cell count (adults: 12%), anemia (adults: 11%)

Hepatic: Increased serum alkaline phosphatase (adults: 9% to 22%), increased serum ALT (adults: 4% to 18%; infants, children, and adolescents: 5%), increased serum AST (adults: 6% to 16%; infants, children, and adolescents: 2%), increased serum bilirubin (adults: 5% to 13%)

Local: Localized phlebitis (adults: 18%)

Renal: Increased serum creatinine (adults: 3% to 11%)

Respiratory: Respiratory failure (adults: 2% to 20%), cough (adults: 6% to 11%), pneumonia (adults: 4% to 11%)

Miscellaneous: Infusion related reaction (20% to 35%), fever (6% to 30%), septic shock (adults: 11% to 14%)

1% to 10%:

Cardiovascular: Hypertension (5% to 9%), atrial fibrillation (<5%), bradycardia (<5%), cardiac arrhythmia (<5%), edema (<5%), flushing (<5%), myocardial infarction (<5%)

Central nervous system: Anxiety (<5%), confusion (<5%), depression (<5%), dizziness (<5%), drowsiness (<5%), fatigue (<5%), insomnia (<5%), seizure (<5%)

Dermatologic: Erythema (5% to 9%), pruritus (infants, children, and adolescents: 6%), skin lesion (<5%), urticaria (<5%), decubitus ulcer (adults: 3% to 5%)

Endocrine & metabolic: Hypomagnesemia (adults: 7%), hyperglycemia (adults: 6%), hypokalemia (5% to 6%), hypercalcemia (<5%), hypervolemia (<5%)

Gastrointestinal: Abdominal pain (4% to 9%), mucosal inflammation (4% to 6%), abdominal distention (<5%), anorexia (<5%), constipation (<5%), decreased appetite (<5%), dyspepsia (<5%), upper abdominal pain (<5%)

Genitourinary: Urinary tract infection (<5%), nephrotoxicity (adults: 3%; serum creatinine ≥2 x baseline value or ≥1 mg/dL in patients with serum creatinine above ULN range)

Hematologic & oncologic: Blood coagulation disorder (<5%), febrile neutropenia (<5%), neutropenia (<5%), petechia (<5%), thrombocytopenia (<5%)

Hepatic: Decreased serum albumin (adults: 7%), hepatic failure (<5%), hepatomegaly (<5%), hepatotoxicity (<5%), hyperbilirubinemia (<5%), jaundice (<5%)

Infection: Sepsis (adults: 5% to 7%), bacteremia (<5%)

Local: Catheter infection (infants, children, and adolescents: 9%), infusion site reaction (<5%; pain/pruritus/swelling)

Neuromuscular & skeletal: Arthralgia (<5%), back pain (<5%), limb pain (<5%), tremor (<5%), weakness (<5%)

Renal: Hematuria (adults: 10%), increased blood urea nitrogen (adults: 4% to 9%), renal failure (<5%)

Respiratory: Dyspnea (adults: 9%), pleural effusion (adults: 9%), respiratory distress (adults: ≤8%), rales (adults: 7%), epistaxis (<5%), hypoxia (<5%), tachypnea (<5%)

<1%, postmarketing, and/or case reports: Anaphylaxis, erythema multiforme, exfoliation of skin, hepatic necrosis, hepatitis, histamine release (including facial swelling, bronchospasm, sensation of warmth), increased gamma-glutamyl transferase, pancreatitis, renal insufficiency, Stevens-Johnson syndrome, swelling, toxic epidermal necrolysis

Contraindications

Hypersensitivity to caspofungin or any component of the formulation

Warnings/Precautions

Concerns related to adverse effects:

• Hepatic effects: Increased transaminases and rare cases of clinically significant hepatic dysfunction (including failure and hepatitis) have been reported in pediatric and adult patients. Monitor liver function tests during therapy; if tests become abnormal or worsen, consider discontinuation.

• Hypersensitivity: Anaphylaxis, other hypersensitivity reactions, histamine-related reactions (eg, angioedema, facial swelling, bronchospasm, rash, sensation of warmth), and cases of Stevens-Johnson syndrome and toxic epidermal necrolysis (some fatal) have been reported. Discontinue if a hypersensitivity reaction occurs. Administer supportive treatment if needed.

Disease-related concerns:

• Hepatic impairment: Use with caution in patients with hepatic impairment. Dosage reduction may be necessary in adults with moderate impairment (Child-Pugh class B); safety and efficacy have not been established in children with any degree of hepatic impairment and adults with severe impairment (Child-Pugh class C).

Special populations:

• Obesity: Data with another echinocandin suggest that clearance increases as a function of weight; higher doses may be necessary in patients with obesity (Hall 2011).

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Solution Reconstituted, Intravenous, as acetate [preservative free]:

Cancidas: 50 mg (1 ea); 70 mg (1 ea)

Generic: 50 mg (1 ea); 70 mg (1 ea)

Generic Equivalent Available: US

Yes

Pricing: US

Solution (reconstituted) (Cancidas Intravenous)

50 mg (per each): $405.25

70 mg (per each): $421.06

Solution (reconstituted) (Caspofungin Acetate Intravenous)

50 mg (per each): $82.80 - $404.40

70 mg (per each): $94.80 - $420.00

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Solution Reconstituted, Intravenous, as acetate:

Cancidas: 50 mg (10.5 mL); 70 mg (10.5 mL)

Generic: 50 mg (1 ea); 70 mg (1 ea)

Administration: Pediatric

Parenteral: IV: Administer by slow IV infusion over 1 hour (manufacturer); higher doses (eg, 150 mg) have been infused over ~2 hours (Ref). Monitor during infusion; isolated cases of possible histamine-related reactions have occurred during clinical trials (rash, flushing, pruritus, facial edema).

Administration: Adult

IV: Infuse slowly, over ~1 hour. Do not administer by IV bolus.

Storage/Stability

Store intact vials at 2°C to 8°C (36°F to 46°F). Reconstituted solution may be stored at ≤25°C (≤77°F) for up to 1 hour prior to preparation of infusion solution. Solutions diluted in NS, 1/2NS, 1/4NS, or LR for infusion should be used within 24 hours when stored at ≤25°C (≤77°F) or within 48 hours when stored at 2°C to 8°C (36°F to 46°F).

Use

Treatment of invasive aspergillosis in patients who are refractory to or intolerant of other therapies; treatment of candidemia, intra-abdominal abscess, peritonitis, and pleural space infection caused by susceptible Candida species; treatment of esophageal candidiasis; empiric therapy of presumed fungal infection in febrile neutropenic patients (All indications: FDA approved in ages ≥3 months and adults); has also been used for prophylaxis of fungal infections in pediatric patients with acute myeloid leukemia or following allogeneic hematopoietic stem cell transplantation.

Metabolism/Transport Effects

None known.

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.

CycloSPORINE (Systemic): May enhance the adverse/toxic effect of Caspofungin. CycloSPORINE (Systemic) may increase the serum concentration of Caspofungin. Caspofungin may increase the serum concentration of CycloSPORINE (Systemic). Management: Weigh potential benefits of caspofungin against a possible elevated risk of hepatotoxicity. Monitor liver function and re-evaluate treatment in patients with abnormal values. Mild transaminase elevations may occur relatively commonly. Risk D: Consider therapy modification

Inducers of Drug Clearance: May decrease the serum concentration of Caspofungin. Management: Consider using an increased caspofungin dose of 70 mg daily in adults (or 70 mg/m2, up to a maximum of 70 mg, daily in pediatric patients) when coadministered with known inducers of drug clearance. Risk D: Consider therapy modification

RifAMPin: May decrease the serum concentration of Caspofungin. Management: Caspofungin prescribing information recommends using a dose of 70 mg daily in adults (or 70 mg/m2, up to a maximum of 70 mg, daily in pediatric patients) who are also receiving rifampin. Risk D: Consider therapy modification

Saccharomyces boulardii: Antifungal Agents (Systemic and Oral [Non-Absorbable]) may diminish the therapeutic effect of Saccharomyces boulardii. Risk X: Avoid combination

Pregnancy Considerations

Based on animal data, in utero exposure to caspofungin may cause fetal harm.

When treatment of invasive Aspergillus or Candida infections is needed during pregnancy, other agents are preferred (HHS [OI adult 2020]; IDSA [Pappas 2016]).

Monitoring Parameters

Periodic liver function tests, serum potassium, CBC, hemoglobin; signs of anaphylaxis or histamine-related reactions

Mechanism of Action

Inhibits synthesis of β(1,3)-D-glucan, an essential component of the cell wall of susceptible fungi. Highest activity is in regions of active cell growth. Mammalian cells do not require β(1,3)-D-glucan, limiting potential toxicity.

Pharmacokinetics (Adult Data Unless Noted)

Distribution: CSF concentrations: Nondetectable [<10 ng/mL (n=1)] (Sáez-Llorens 2009)

Protein binding: ~97% to albumin

Metabolism: Slowly, via hydrolysis and N-acetylation as well as by spontaneous degradation, with subsequent metabolism to component amino acids. Overall metabolism is extensive.

Half-life elimination: Beta (distribution): 9 to 11 hours (~8 hours in children <12 years); Terminal: 40 to 50 hours; beta phase half-life is 32% to 43% lower in pediatric patients than in adult patients

Excretion: Urine (41%; primarily as metabolites, ~1% of total dose as unchanged drug); feces (35%; primarily as metabolites)

Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)

Altered kidney function: AUC is increased 30% to 49% in patients with CrCl ≤49 mL/minute after administration of a single 70 mg dose. No effect on caspofungin concentrations was seen in patients with mild to end-stage renal impairment after administration of multiple daily doses.

Hepatic function impairment: AUC is increased by ~55% in patients with mild hepatic impairment (Child-Pugh class A) and by 76% in patients with moderate hepatic impairment (Child-Pugh class B).

Older adult: AUC is increased by ~28%.

Sex: AUC in women was ~22% higher than in men after repeat dosing.

Obesity: Data with another echinocandin suggest that clearance increases as a function of weight (Hall 2011). From a small study of patients receiving caspofungin in the surgical ICU, body weight >75 kg was an independent predictor for a lower 24-hour trough concentration (Nguyen 2007).

Brand Names: International
International Brand Names by Country
For country code abbreviations (show table)

  • (AE) United Arab Emirates: Cancidas;
  • (AR) Argentina: Cancidas | Caspofungina sandoz;
  • (AT) Austria: Cancidas | Caspofungin hikma | Caspofungin mylan | Caspofungin ratiopharm | Caspofungin stada;
  • (AU) Australia: Cancidas | Caspofungin an | Caspofungin myx;
  • (BE) Belgium: Cancidas | Caspofungin sandoz | Caspofungin teva | Caspofungine mylan | Caspofungine noridem;
  • (BG) Bulgaria: Cancidas;
  • (BR) Brazil: Acetato de caspofungina | Berk | Cancidas;
  • (CH) Switzerland: Cancidas | Caspofungin mepha | Caspofungin mylan | Caspofungin sandoz;
  • (CL) Chile: Cancidas | Casfucid | Caspodyan | Caspofungina | Caspovitae | Sanicid | Suvepur;
  • (CN) China: Cancidas;
  • (CO) Colombia: Cafugin | Cancidas | Capsin | Caspofungina | Caspofungina acetato | Caspongyn | Caspovitae | Caxofu | Estasin | Kafum | Suvepur;
  • (CZ) Czech Republic: Cancidas | Caspofungin teva;
  • (DE) Germany: Cancidas | Caspofungin | Caspofungin amneal | Caspofungin beta | Caspofungin demo | Caspofungin hikma | Caspofungin inresa | Caspofungin lorien | Caspofungin mylan | Caspofungin Pharmore | Caspofungin ratiopharm | Caspofungin sandoz | Caspofungin stada | Caspofungin sun | Caspofungin tillomed | Caspofungin zentiva;
  • (DO) Dominican Republic: Cancidas;
  • (EC) Ecuador: Acetato de caspofungina | Cancidas | Caspof | Caspofungina | Caspofunzel | Caspovitae | Caxofu | Fungicas;
  • (EE) Estonia: Cancidas | Caspofungin | Caspofungin sandoz | Dalvocans;
  • (EG) Egypt: Cancidas;
  • (ES) Spain: Cancidas | Caspofungina aristo | Caspofungina dr. reddy's | Caspofungina genfarma | Caspofungina Lorien | Caspofungina mylan | Caspofungina normon | Caspofungina sandoz | Caspofungina stada | Caspofungina sun | Caspofungina teva | Caspofungina tevagen;
  • (ET) Ethiopia: Cancidas;
  • (FI) Finland: Cancidas | Caspofungin lorien | Caspofungin mylan | Caspofungin orion | Caspofungin stada;
  • (FR) France: Cancidas | Caspofungine Accord | Caspofungine altan | Caspofungine dr.reddy's | Caspofungine eg | Caspofungine fresenius kabi | Caspofungine mylan | Caspofungine Ohre pharma | Caspofungine sun | Caspofungine teva;
  • (GB) United Kingdom: Cancidas | Caspofungin | Caspofungin Dr. Reddy's;
  • (GR) Greece: Cancidas | Caspofungin accord | Caspofungin/demo | Caspofungin/teva | Fungizor;
  • (HK) Hong Kong: Cancidas;
  • (HR) Croatia: Cancidas;
  • (HU) Hungary: Cancidas | Caspofungin onkogen | Caspofungin ratiopharm | Dalvocans;
  • (ID) Indonesia: Cancidas;
  • (IE) Ireland: Caspofungin accord | Caspofungin Clonmel | Caspofungin Rowex;
  • (IN) India: Auxicasp | Bdcaspo | Cagin | Cancidas | Canducid | Capofin | Casfung | Casfungen | Casocan | Caspogard | Caspogin | Casponex | Casporan | Caspotaz | Casviogin | Savacap | Wofungin;
  • (IT) Italy: Cancidas | Caspofungin | Caspofungin Dr. Reddy's | Caspofungin eg | Caspofungin hikma | Caspofungin Laboratorios Lorien | Caspofungin medac | Caspofungin mylan | Caspofungin sandoz | Caspofungin sun;
  • (JO) Jordan: Cancidas;
  • (JP) Japan: Cancidas;
  • (KE) Kenya: Cancidas | Casdin | Casfung | Caspogin | Kasiniv | Spogin;
  • (KR) Korea, Republic of: Cancidas | Penmix caspofungin acetate;
  • (KW) Kuwait: Cancidas;
  • (LB) Lebanon: Cancidas;
  • (LT) Lithuania: Cancidas | Dalvocans;
  • (MX) Mexico: Cancidas | Caspofungin | Caspofungina | Fhanigun | Fiorella | Fuzitran | Karpilmex | Monmix | Suvepur | Tyspercan;
  • (MY) Malaysia: Cancidas;
  • (NG) Nigeria: Cancidas;
  • (NL) Netherlands: Cancidas | Caspofungine | Caspofungine Accord | Caspofungine cf | Caspofungine mylan | Caspofungine teva;
  • (NO) Norway: Cancidas | Caspofungin | Caspofungin lorien | Caspofungin mylan;
  • (NZ) New Zealand: Cancidas | Caspofungin;
  • (PE) Peru: Cancidas | Caspovitae;
  • (PH) Philippines: Cancidas;
  • (PL) Poland: Cancidas | Caspofungin adamed | Caspofungin Fresenius Kabi | Caspofungin mylan | Caspofungin ranbax | Caspofungin Solinea | Caspofungin stada | Caspofungin zentiva | Dalvocans;
  • (PR) Puerto Rico: Cancidas;
  • (PT) Portugal: Cancidas | Caspofungin generis | Caspofungina farmoz | Caspofungina hikma | Caspofungina mylan | Caspofungina teva;
  • (PY) Paraguay: Bdcaspo;
  • (QA) Qatar: Cancidas;
  • (RO) Romania: Cancidas | Caspofungina mylan | Caspofungina sandoz | Caspofungina stada | Caspofungina terapia | Caspofungina zentiva | Dalvocans;
  • (RU) Russian Federation: Cancidas | Cansidas | Caspofungin | Caspofungin nativ | Maxcand;
  • (SA) Saudi Arabia: Afundas l | Canvas | Caspofungin | Fungiska;
  • (SE) Sweden: Cancidas | Caspofungin mylan | Caspofungin orion | Caspofungin sandoz | Caspofungin stada | Caspofungin teva | Kaspofungin lorien;
  • (SG) Singapore: Cancidas;
  • (SI) Slovenia: Cancidas | Caspofungin teva | Kaspofungin stada;
  • (SK) Slovakia: Cancidas | Caspofungin mylan | Caspofungin sandoz | Caspofungin teva;
  • (TH) Thailand: Cancidas;
  • (TN) Tunisia: Cancidas;
  • (TR) Turkey: Afundas l | Cancas | Cancidas | Casfugin | Caspobiem | Caspopol | Fungidas;
  • (TW) Taiwan: Cancidas;
  • (UA) Ukraine: Cancidas;
  • (UY) Uruguay: Cancidas | Casfucid;
  • (VE) Venezuela, Bolivarian Republic of: Cancidas;
  • (ZA) South Africa: Casfolred | Caspofungin | Msd caspofungin
  1. Aguilar G, Ferriols R, Lozano A, et al. Optimal doses of caspofungin during continuous venovenous hemodiafiltration in critically ill patients. Crit Care. 2017;21(1):17. doi:10.1186/s13054-016-1594-9 [PubMed 28132647]
  2. Aronoff GR, Bennett WM, Berns JS, et al. Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children. 5th ed. Philadelphia, PA: American College of Physicians; 2007:61, 153.
  3. Aslam S, Rotstein C; AST Infectious Disease Community of Practice. Candida infections in solid organ transplantation: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019;33(9):e13623. doi:10.1111/ctr.13623 [PubMed 31155770]
  4. Betts RF, Nucci M, Talwar D, et al, “A Multicenter, Double-Blind Trial of a High-Dose Caspofungin Treatment Regimen Versus a Standard Caspofungin Treatment Regimen for Adult Patients With Invasive Candidiasis,” Clin Infect Dis, 2009, 48(12):1676-84. [PubMed 19419331]
  5. Bradley JS and Nelson JD, eds. Nelson's Pediatric Antimicrobial Therapy. 25th ed. Itasca, IL: American Academy of Pediatrics; 2019.
  6. Cancidas (caspofungin) [prescribing information]. Rahway, NJ: Merck Sharp & Dohme LLC; May 2022.
  7. Candidiasis (Mucocutaneous). In: US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/Adult_OI.pdf. Accessed June 16, 2021.
  8. Cornely OA, Lasso M, Betts R, et al. Caspofungin for the treatment of less common forms of invasive candidiasis. J Antimicrob Chemother. 2007;60(2):363-369. doi:10.1093/jac/dkm169 [PubMed 17526917]
  9. Döring M, Hartmann U, Erbacher A, Lang P, Handgretinger R, Müller I. Caspofungin as antifungal prophylaxis in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation: a retrospective analysis. BMC Infect Dis. 2012;12:151. [PubMed 22747637]
  10. Evans L, Rhodes A, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Intensive Care Med. 2021;47(11):1181-1247. doi:10.1007/s00134-021-06506-y [PubMed 34599691]
  11. Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.
  12. Fisher BT, Zaoutis T, Dvorak CC, et al. Effect of caspofungin vs fluconazole prophylaxis on invasive fungal disease among children and young adults with acute myeloid leukemia: a randomized clinical trial. JAMA. 2019;322(17):1673-1681. [PubMed 31688884]
  13. Fishman JA, Alexander BD. Prophylaxis of infections in solid organ transplantation. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed July 30, 2021.
  14. Fortún J, Muriel A, Martín-Dávila P, et al; Grupo de Estudio de Infección en Pacientes Trasplantados-Grupo de Estudio de Micología Médica (Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica), and Red Española de Investigación en Patología Infecciosa. Caspofungin versus fluconazole as prophylaxis of invasive fungal infection in high-risk liver transplantation recipients: a propensity score analysis. Liver Transpl. 2016;22(4):427-435. doi:10.1002/lt.24391 [PubMed 26709146]
  15. Freifeld AG, Bow EJ, Sepkowitz KA, et al; Infectious Diseases Society of America. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2011;52(4):e56-e93. doi:10.1093/cid/cir073 [PubMed 21258094]
  16. Gould FK, Denning DW, Elliott TS, et al, “Guidelines for the Diagnosis and Antibiotic Treatment of Endocarditis in Adults: A Report of the Working Party of the British Society for Antimicrobial Chemotherapy,” J Antimicrob Chemother, 2012, 67(2):269-89. [PubMed 22086858]
  17. Gustot T, Ter Heine R, Brauns E, Cotton F, Jacobs F, Brüggemann RJ. Caspofungin dosage adjustments are not required for patients with Child-Pugh B or C cirrhosis. J Antimicrob Chemother. 2018;73(9):2493-2496. doi:10.1093/jac/dky189 [PubMed 29860319]
  18. Hall RG, Swancutt MA, Gumbo T. Fractal geometry and the pharmacometrics of micafungin in overweight, obese, and extremely obese people. Antimicrob Agents Chemother. 2011;55(11):5107-5112. doi:10.1128/AAC.05193-11 [PubMed 21876061]
  19. Heintz BH, Matzke GR, Dager WE. Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis. Pharmacotherapy. 2009;29(5):562-577. [PubMed 19397464]
  20. Husain S, Camargo JF. Invasive aspergillosis in solid-organ transplant recipients: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019;33(9):e13544. doi:10.1111/ctr.13544 [PubMed 30900296]
  21. Iosifidis E, Papachristou S, Roilides E. Advances in the treatment of mycoses in pediatric patients. J Fungi (Basel). 2018;4(4):115. [PubMed 30314389]
  22. Jeon GW, Sin JB. Successful caspofungin treatment of persistent candidemia in extreme prematurity at 23 and 24 weeks' gestation. J Formos Med Assoc. 2014;113(3):191-194. [PubMed 24534016]
  23. Kauffman CA. Esophageal candidiasis in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. https://www.uptodate.com. Accessed March 14, 2022c.
  24. Kauffman CA. Oropharyngeal candidiasis in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. https://www.uptodate.com. Accessed June 17, 2021d.
  25. Lehrnbecher T, Robinson P, Fisher B, et al. Guideline for the management of fever and neutropenia in children with cancer and hematopoietic stem-cell transplantation recipients: 2017 update. J Clin Oncol. 2017;35(18):2082-2094. [PubMed 28459614]
  26. Maertens J, Glasmacher A, Herbrecht R, et al. Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis. Cancer. 2006;107(12):2888-2897. [PubMed 17103444]
  27. Maertens J, Raad I, Petrikkos G, et al; Caspofungin Salvage Aspergillosis Study Group. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis. 2004;39(11):1563-1571. doi:10.1086/423381 [PubMed 15578352]
  28. Marr KA, Boeckh M, Carter RA, Kim HW, Corey L. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis. 2004;39(6):797-802. doi:10.1086/423380 [PubMed 15472810]
  29. Marr KA, Schlamm HT, Herbrecht R, et al. Combination antifungal therapy for invasive aspergillosis: a randomized trial. Ann Intern Med. 2015;162(2):81-89. doi:10.7326/M13-2508 [PubMed 25599346]
  30. Mattiuzzi GN, Alvarado G, Giles FJ, et al. Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies. Antimicrob Agents Chemother. 2006;50(1):143-147. doi:10.1128/AAC.50.1.143-147.2006 [PubMed 16377679]
  31. Maximova N, Schillani G, Simeone R, Maestro A, Zanon D. Comparison of efficacy and safety of caspofungin versus micafungin in pediatric allogeneic stem cell transplant recipients: a retrospective analysis. Adv Ther. 2017;34(5):1184-1199. [PubMed 28429246]
  32. Mazuski JE, Tessier JM, May AK, et al. The Surgical Infection Society revised guidelines on the management of intra-abdominal infection. Surg Infect (Larchmt). 2017;18(1):1-76. doi:10.1089/sur.2016.261 [PubMed 28085573]
  33. Mistry GC, Migoya E, Deutsch PJ, et al. Single- and multiple-dose administration of caspofungin in patients with hepatic insufficiency: implications for safety and dosing recommendations. J Clin Pharmacol. 2007;47(8):951-961. [PubMed 17660480]
  34. Mohamed WA, Ismail M. A randomized, double-blind, prospective study of caspofungin vs. amphotericin B for the treatment of invasive candidiasis in newborn infants. J Trop Pediatr. 2012;58(1):25-30. [PubMed 21355042]
  35. Mora-Duarte J, Betts R, Rotstein C, et al; Caspofungin Invasive Candidiasis Study Group. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med. 2002;347(25):2020-2029. [PubMed 12490683]
  36. Nguyen TH, Hoppe-Tichy T, Geiss HK, et al. Factors influencing caspofungin plasma concentrations in patients of a surgical intensive care unit. J Antimicrob Chemother. 2007;60(1):100-106. doi:10.1093/jac/dkm125 [PubMed 17525052]
  37. Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62(4):e1-e50. doi: 10.1093/cid/civ933 [PubMed 26679628]
  38. Patterson TF. Treatment and prevention of invasive aspergillosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed January 5, 2022.
  39. Patterson TF, Thompson GR 3rd, Denning DW, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;63(4):e1-e60. doi:10.1093/cid/ciw326 [PubMed 27365388]
  40. Pérez-Pitarch A, Ferriols-Lisart R, Aguilar G, Ezquer-Garín C, Belda FJ, Guglieri-López B. Dosing of caspofungin based on a pharmacokinetic/pharmacodynamic index for the treatment of invasive fungal infections in critically ill patients on continuous venovenous haemodiafiltration. Int J Antimicrob Agents. 2018;51(1):115-121. doi:10.1016/j.ijantimicag.2017.05.013 [PubMed 28666752]
  41. Refer to manufacturer's labeling.
  42. Roger C, Wallis SC, Muller L, et al. Caspofungin population pharmacokinetics in critically ill patients undergoing continuous veno-venous haemofiltration or haemodiafiltration. Clin Pharmacokinet. 2017;56(9):1057-1068. doi:10.1007/s40262-016-0495-z [PubMed 28035589]
  43. Sáez-Llorens X, Macias M, Maiya P, et al, "Pharmacokinetics and Safety of Caspofungin in Neonates and Infants Less Than 3 Months of Age," Antimicrob Agents Chemother, 2009, 53(3):869-75. [PubMed 19075070]
  44. Science M, Robinson PD, MacDonald T, Rassekh SR, Dupuis LL, Sung L. Guideline for primary antifungal prophylaxis for pediatric patients with cancer or hematopoietic stem cell transplant recipients. Pediatr Blood Cancer. 2014;61(3):393-400. [PubMed 24424789]
  45. Singh N, Limaye AP, Forrest G, et al. Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study. Transplantation. 2006;81(3):320-326. doi:10.1097/01.tp.0000202421.94822.f7 [PubMed 16477215]
  46. Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis. 2010;50(2):133-164. doi:10.1086/649554 [PubMed 20034345]
  47. Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America [published online June 18, 2014]. Clin Infect Dis. 2014;59(2):e10-52. doi:10.1093/cid/ciu296 [PubMed 24947530]
  48. Stone EA, Fung HB, and Kirschenbaum HL, “Caspofungin: An Echinocandin Antifungal Agent,” Clin Ther, 2002, 24(3):351-77. [PubMed 11952021]
  49. Taplitz RA, Kennedy EB, Bow EJ, et al. Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA clinical practice guideline update. J Clin Oncol. 2018;36(30):3043-3054. doi:10.1200/JCO.18.00374 [PubMed 30179565]
  50. US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in Adults and Adolescents With HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/whats-new. Updated November 21, 2019. Accessed January 22, 2020.
  51. US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in Adults and Adolescents With HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/whats-new. Accessed April 29, 2020.
  52. US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children. https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-pediatric-opportunistic-infections/whats-new. Updated December 2016.
  53. US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Guidelines for prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children. https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-pediatric-opportunistic-infections/whats-new. Updated December 9, 2019. Accessed January 22, 2020.
  54. Vazquez, JA. Candida osteoarticular infections. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed January 10, 2022a.
  55. Vazquez JA. Management of candidemia and invasive candidiasis in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed July 27, 2022b.
  56. Villanueva A, Gotuzzo E, Arathoon EG, et al. A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. Am J Med. 2002;113(4):294-299. doi:10.1016/s0002-9343(02)01191-9 [PubMed 12361815]
  57. Walsh TJ, Adamson PC, Seibel NL, et al, "Pharmacokinetics, Safety, and Tolerability of Caspofungin in Children and Adolescents," Antimicrob Agents Chemother, 2005, 49(11):4536-45. [PubMed 16251293]
  58. Walsh TJ, Teppler H, Donowitz GR, et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med. 2004;351(14):1391-1402. doi:10.1056/NEJMoa040446 [PubMed 15459300]
  59. Weiler S, Seger C, Pfisterer H, et al. Pharmacokinetics of caspofungin in critically ill patients on continuous renal replacement therapy. Antimicrob Agents Chemother. 2013;57(8):4053-4057. doi:10.1128/AAC.00335-13 [PubMed 23733471]
  60. Wingard JR. Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients). Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed July 30, 2021.
Topic 12914 Version 236.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟